Constitutive expression of Fas ligand in large granular lymphocyte leukaemia

被引:68
作者
Perzova, R
Loughran, TP
机构
[1] SUNY SYRACUSE,VET ADM HOSP,SYRACUSE,NY
[2] SUNY SYRACUSE,DEPT MED,SYRACUSE,NY
[3] SUNY SYRACUSE,DEPT MICROBIOL IMMUNOL,SYRACUSE,NY
关键词
Fas ligand; LGL leukaemia; Fas;
D O I
10.1046/j.1365-2141.1997.d01-2113.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The T-cell type of large granular lymphocyte (LGL) leukaemia is a lymphoproliferative disorder characterized by clonal proliferation of CD3(+) LGL, which is often associated with autoimmune disorders. Phenotypic and functional data suggest that leukaemic CD3(+) LGL represent activated cytotoxic T lymphocytes (CTL). One mechanism whereby CTL mediate target cell killing is through the Fas/Fas ligand apoptotic pathway. Fas ligand is expressed by CTL only after activation. In this study we examined seven patients with LGL leukaemia for expression of Fas ligand gene transcripts using reverse transcriptase-polymerase chain reaction (RT-PCR) analyses. We found constitutive expression of Fas ligand gene transcripts in each of the seven patients. Similar up-regulation of Fas ligand gene expression has been observed in mice with autoimmune lymphoproliferative syndromes caused by Fas mutations. However, sequence analyses of the death domain of the Fas gene in LGL leukaemia patients revealed no evidence for mutations. Our findings provide further support for the hypothesis that leukaemic LGL are CTL activated by chronic antigenic stimulation. Constitutive expression of Fas ligand may contribute to the pathogenesis of the neutropenia observed in LGL leukaemia.
引用
收藏
页码:123 / 126
页数:4
相关论文
共 26 条
[21]   ANTIGEN-SPECIFIC CYTO-TOXIC T-CELL AND ANTIGEN-SPECIFIC PROLIFERATING T-CELL CLONES CAN BE INDUCED TO CYTOLYTIC ACTIVITY BY MONOCLONAL-ANTIBODIES AGAINST T3 [J].
SPITS, H ;
YSSEL, H ;
LEEUWENBERG, J ;
DEVRIES, JE .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1985, 15 (01) :88-91
[22]  
SUDA T, 1995, J IMMUNOL, V154, P3806
[23]   MOLECULAR-CLONING AND EXPRESSION OF THE FAS LIGAND, A NOVEL MEMBER OF THE TUMOR-NECROSIS-FACTOR FAMILY [J].
SUDA, T ;
TAKAHASHI, T ;
GOLSTEIN, P ;
NAGATA, S .
CELL, 1993, 75 (06) :1169-1178
[24]   Fas ligand in human serum [J].
Tanaka, M ;
Suda, T ;
Haze, K ;
Nakamura, N ;
Sato, K ;
Kimura, F ;
Motoyoshi, K ;
Mizuki, M ;
Tagawa, S ;
Ohga, S ;
Hatake, K ;
Drummond, AH ;
Nagata, S .
NATURE MEDICINE, 1996, 2 (03) :317-322
[25]   TCR CD3 COUPLING TO FAS-BASED CYTOTOXICITY [J].
VIGNAUX, F ;
VIVIER, E ;
MALISSEN, B ;
DEPRAETERE, V ;
NAGATA, S ;
GOLSTEIN, P .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 181 (02) :781-786
[26]   LYMPHOPROLIFERATION DISORDER IN MICE EXPLAINED BY DEFECTS IN FAS ANTIGEN THAT MEDIATES APOPTOSIS [J].
WATANABEFUKUNAGA, R ;
BRANNAN, CI ;
COPELAND, NG ;
JENKINS, NA ;
NAGATA, S .
NATURE, 1992, 356 (6367) :314-317